Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 15/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.38 |
| ▸ | SKP1 | P63208 | 2/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24879320 | 1.00 | RET (0.47) | RETCKS1BSKP1SKP2RAF1 | |
| SCHEMBL29686486 | 0.87 | RET (0.47) | RETCKS1BSKP1SKP2RAF1 | |
| SCHEMBL20069375 | 0.87 | RET (0.47) | RETCKS1BSKP1SKP2RAF1 | |
| SCHEMBL27453327 | 0.86 | RET (0.47) | RETCKS1BSKP1SKP2RAF1 | |
| SCHEMBL30194848 | 0.86 | RET (0.47) | RETCKS1BSKP1SKP2RAF1 | |
| SCHEMBL6698757 | 0.85 | RET (0.52) | RET | |
| SCHEMBL30511931 | 0.83 | RET (0.45) | RETCKS1BSKP1SKP2RAF1 | |
| SCHEMBL19785238 | 0.83 | RET (0.45) | RETCKS1BSKP1SKP2RAF1 | |
| SCHEMBL24878910 | 0.83 | CKS1B (0.41) | RETCKS1BSKP1SKP2GPR119 | |
| SCHEMBL30111113 | 0.83 | CKS1B (0.41) | RETCKS1BSKP1SKP2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | RET 107/4885CKS1B 1581/4885SKP1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.